Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo.

Endocrinology and metabolism (Seoul, Korea)

Starenki D, Park JI.
PMID: 26485469
Endocrinol Metab (Seoul). 2015 Dec;30(4):593-603. doi: 10.3803/EnM.2015.30.4.593. Epub 2015 Oct 20.

BACKGROUND: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. Not all patients with progressive MTC respond to current therapy inhibiting RET, demanding additional therapeutic strategies. We recently demonstrated...

Cite
Starenki D, Park JI. Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Endocrinol Metab (Seoul). 2015;30(4):593-603doi: 10.3803/EnM.2015.30.4.593.
Starenki, D., & Park, J. I. (2015). Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Endocrinology and metabolism (Seoul, Korea), 30(4), 593-603. https://doi.org/10.3803/EnM.2015.30.4.593
Starenki, Dmytro, and Park, Jong In. "Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo." Endocrinology and metabolism (Seoul, Korea) vol. 30,4 (2015): 593-603. doi: https://doi.org/10.3803/EnM.2015.30.4.593
Starenki D, Park JI. Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Endocrinol Metab (Seoul). 2015 Dec;30(4):593-603. doi: 10.3803/EnM.2015.30.4.593. Epub 2015 Oct 20. PMID: 26485469; PMCID: PMC4722416.
Copy Download .nbib Format: NLM
Growth arrest signaling of the Raf/MEK/ERK pathway in cancer.

Frontiers in biology

Park JI.
PMID: 24999356
Front Biol (Beijing). 2014 Feb;9(2):95-103. doi: 10.1007/s11515-014-1299-x.

The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway has a pivotal role in facilitating cell proliferation, and its deregulated activation is a central signature of many epithelial cancers. However paradoxically, sustained activity of Raf/MEK/ERK can also result in growth arrest in...

Cite
Park JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing). 2014;9(2):95-103doi: 10.1007/s11515-014-1299-x.
Park, J. I. (2014). Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Frontiers in biology, 9(2), 95-103. https://doi.org/10.1007/s11515-014-1299-x
Park, Jong-In. "Growth arrest signaling of the Raf/MEK/ERK pathway in cancer." Frontiers in biology vol. 9,2 (2014): 95-103. doi: https://doi.org/10.1007/s11515-014-1299-x
Park JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing). 2014 Feb;9(2):95-103. doi: 10.1007/s11515-014-1299-x. PMID: 24999356; PMCID: PMC4079089.
Copy Download .nbib Format: NLM
The Role of STAT3 in Thyroid Cancer.

Cancers

Sosonkina N, Starenki D, Park JI.
PMID: 24662939
Cancers (Basel). 2014 Mar 06;6(1):526-44. doi: 10.3390/cancers6010526.

Thyroid cancer is the most common endocrine malignancy and its global incidence rates are rapidly increasing. Although the mortality of thyroid cancer is relatively low, its rate of recurrence or persistence is relatively high, contributing to incurability and morbidity...

Cite
Sosonkina N, Starenki D, Park JI. The Role of STAT3 in Thyroid Cancer. Cancers (Basel). 2014;6(1):526-44doi: 10.3390/cancers6010526.
Sosonkina, N., Starenki, D., & Park, J. I. (2014). The Role of STAT3 in Thyroid Cancer. Cancers, 6(1), 526-44. https://doi.org/10.3390/cancers6010526
Sosonkina, Nadiya, et al. "The Role of STAT3 in Thyroid Cancer." Cancers vol. 6,1 (2014): 526-44. doi: https://doi.org/10.3390/cancers6010526
Sosonkina N, Starenki D, Park JI. The Role of STAT3 in Thyroid Cancer. Cancers (Basel). 2014 Mar 06;6(1):526-44. doi: 10.3390/cancers6010526. PMID: 24662939; PMCID: PMC3980610.
Copy Download .nbib Format: NLM
Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.

Genes & genomics

Sosonkina N, Hong SK, Starenki D, Park JI.
PMID: 25530832
Genes Genomics. 2014 Dec;36(6):829-841. doi: 10.1007/s13258-014-0217-6.

Neuroendocrine (NE) lung tumors comprise 20-25% of all invasive lung malignancies. Currently, no effective treatments are available to cure these tumors, and it is necessary to identify a molecular alteration(s) that characterizes NE lung tumor cells. We aimed to...

Cite
Sosonkina N, Hong SK, Starenki D, et al. Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics. 2014;36(6):829-841doi: 10.1007/s13258-014-0217-6.
Sosonkina, N., Hong, S. K., Starenki, D., & Park, J. I. (2014). Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes & genomics, 36(6), 829-841. https://doi.org/10.1007/s13258-014-0217-6
Sosonkina, Nadiya, et al. "Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines." Genes & genomics vol. 36,6 (2014): 829-841. doi: https://doi.org/10.1007/s13258-014-0217-6
Sosonkina N, Hong SK, Starenki D, Park JI. Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics. 2014 Dec;36(6):829-841. doi: 10.1007/s13258-014-0217-6. PMID: 25530832; PMCID: PMC4270057.
Copy Download .nbib Format: NLM
Pediatric Medullary Thyroid Carcinoma.

Journal of pediatric oncology

Starenki D, Park JI.
PMID: 27014708
J Pediatr Oncol. 2015;3(2):29-37. doi: 10.14205/2309-3021.2015.03.02.1.

Medullary thyroid carcinoma (MTC), which originates from thyroid parafollicular C cells, accounts for 3 to 5% of thyroid malignancies. MTC occurs either sporadically or in an inherited autosomal dominant manner. Hereditary MTC occurs as a familial MTC or as...

Cite
Starenki D, Park JI. Pediatric Medullary Thyroid Carcinoma. J Pediatr Oncol. 2015;3(2):29-37doi: 10.14205/2309-3021.2015.03.02.1.
Starenki, D., & Park, J. I. (2015). Pediatric Medullary Thyroid Carcinoma. Journal of pediatric oncology, 3(2), 29-37. https://doi.org/10.14205/2309-3021.2015.03.02.1
Starenki, Dmytro, and Park, Jong-In. "Pediatric Medullary Thyroid Carcinoma." Journal of pediatric oncology vol. 3,2 (2015): 29-37. doi: https://doi.org/10.14205/2309-3021.2015.03.02.1
Starenki D, Park JI. Pediatric Medullary Thyroid Carcinoma. J Pediatr Oncol. 2015;3(2):29-37. doi: 10.14205/2309-3021.2015.03.02.1. PMID: 27014708; PMCID: PMC4803041.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries